Can China Ace The CAR-T Race?

 
• By Brian Yang

Helped by Nanjing Legend's multimillion dollar deal with J&J, China has now overtaken the US in number of clinical trials using CAR-T cell approaches to treating cancers, but could uncertainties derail the country's CAR-T train from steaming ahead?

Destruction of leukaemia cell, conceptual image. 3D illustration which can be used to illustrate blood cancer treatment
CHINA OVERTAKES THE US IN CAR-T TRIALS

Armed with deals from a variety of multinationals and a flurry of domestic development activity, China is poised to become a major force in treating cancers using the latest CAR-T technology.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia